Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
B-cell receptors (BCRs) specific for conformational epitopes on the norovirus VP1 protein are specialized immune receptors that play a central role in the adaptive immune response against norovirus infections. The VP1 protein, which forms the viral capsid, contains a protruding (P) domain that is the primary site for interaction with host cell receptors, specifically histo-blood group antigens (HBGAs) (Parra et al., 2017, Journal of Virology). BCRs recognize complex three-dimensional arrangements of amino acids on this P domain, and their activation is essential for the generation of high-affinity neutralizing antibodies that prevent viral attachment (Lindesmith et al., 2012, Journal of Virology). In therapeutic development, these BCRs are the intended targets of norovirus vaccines, such as virus-like particle (VLP) and mRNA-based candidates, which aim to stimulate the production of memory B cells and long-lived plasma cells (Atmar et al., 2011, New England Journal of Medicine). The specificity of these receptors is a major challenge due to the significant antigenic diversity and rapid evolution of norovirus strains, particularly the GII.4 lineage (Debbink et al., 2012, Journal of Virology). Consequently, drug development focuses on identifying conserved conformational epitopes that can elicit broad-spectrum BCR activation to provide cross-genotype protection (Moderna, 2024, Pipeline Update). These receptors are also the basis for developing therapeutic monoclonal antibodies intended for passive immunization in immunocompromised individuals. Monitoring the frequency and affinity of these BCRs serves as a critical metric for evaluating vaccine efficacy in clinical trials.
Antigenic stimulation of the B-cell receptor by norovirus VP1 epitopes triggers intracellular signaling cascades that lead to B-cell proliferation, affinity maturation, and differentiation into antibody-secreting plasma cells and memory B cells.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B-cell receptor (BCR) specific for norovirus VP1 conformational epitopes (BCR-NV-VP1).